During the past decade, GISL Trial Office conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "GISL Trial Office" are "Chronic Lymphocytic Leukemia Stage A(0)" (1 trials), "Chronic Lymphocytic Leukemia Stage A(I)" (1 trials), "Chronic Lymphocytic Leukemia Stage A(II)" (1 trials) and "High-Grade Lymphomas" (1 trials). Many other conditions were trialed in "GISL Trial Office" in a lesser frequency.

Most popular intervention types in "GISL Trial Office" are "Drug" (1 trials). Other intervention types were less common.

The name of intervention was led by "HDS vs ProMECE/CytaBOM" (1 trials). Other intervention names were less common.

The vast majority of trials in "GISL Trial Office" are 2 trials for "All" genders.

Currently, there are NaN active trials in "GISL Trial Office". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in GISL Trial Office, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in GISL Trial Office, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".